Scarica l'app Stockscreener
1.20
0.01%
0.000100
Precedente Chiudi:
$1.1999
Aprire:
$1.2
Volume 24 ore:
68,774
Relative Volume:
1.35
Capitalizzazione di mercato:
$7.08M
Reddito:
-
Utile/perdita netta:
$-12.89M
Rapporto P/E:
-0.4743
EPS:
-2.53
Flusso di cassa netto:
$-11.95M
1 W Prestazione:
-3.23%
1M Prestazione:
-3.23%
6M Prestazione:
-17.81%
1 anno Prestazione:
-40.89%
Intervallo 1D:
$1.0918
$1.20
Intervallo di 1 settimana:
$1.0918
$1.30
Portata 52W:
$0.925
$2.6702
Plus Therapeutics Inc Stock (PSTV) Company Profile
Nome
Plus Therapeutics Inc
Settore
Industria
Telefono
737.255.7194
Indirizzo
4200 MARATHON BLVD., AUSTIN, TX
Confronta PSTV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
1.20 | 7.08M | 0 | -12.89M | -11.95M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-01-25 | Iniziato | Ladenburg Thalmann | Buy |
| 2020-10-16 | Iniziato | Maxim Group | Buy |
Plus Therapeutics Inc Borsa (PSTV) Ultime notizie
Plus Therapeutics appoints new Chief Development Officer By Investing.com - Investing.com Nigeria
Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer - citybiz
Plus Therapeutics appoints new Chief Development Officer - Investing.com India
Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer's Candidate, Zervimesine (CT1812) - The Manila Times
Can This Veteran Drug Developer Transform Plus Therapeutics' Clinical Pipeline? - StockTitan
Stromal Vascular Fraction Market Set to Grow Significantly, - GlobeNewswire
Plus Therapeutics, Inc. Appoints Michael Rosol as Chief Development Officer -February 20, 2025 at 07:30 am EST - Marketscreener.com
Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program - GlobeNewswire
Plus Therapeutics secures $5.7 million for cancer trials - Investing.com India
Plus Therapeutics Secures $3.7M in Convertible Notes Deal - TipRanks
Plus Therapeutics Secures $3.7 Million in Private Placement Financing and $2.0 Million Advance from CPRIT for Clinical Development of CNS Cancer Treatments - Nasdaq
Plus Therapeutics Lands $5.7M Strategic Investment to Accelerate Cancer Treatment Breakthrough - StockTitan
Week Ahead (Aug.16-20): FATE, PSTV To Present Data, Will AXSM Get FDA Nod? - RTTNews
Plus Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights - br.ADVFN.com
Plus Therapeutics (NASDAQ:PSTV) Shares Down 1.3% – Here’s Why - Defense World
CARsgen's First Enrolled Subject in the THANK-u Plus™ Platform-Based Allogeneic CAR-T Trial Achieves sCR at Week 4 - Yahoo Finance
The CRISPR companies are not OK - STAT
Glioma Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight - EIN News
LD Micro 360 Companies Set to Present this Week - ACCESS Newswire
Elevar Therapeutics Presents Results from Post-Hoc Analysis of CARES-310 Study Evaluating the Impact of Viral and Non-Viral Etiology on Survival in Hepatocellular Carcinoma - Yahoo Finance
MiNK Therapeutics Targets Immune Reconstitution to Combat - GlobeNewswire
MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI - Yahoo Finance UK
Leptomeningeal Metastases Pipeline Analysis, Clinical - openPR
Leptomeningeal Metastases Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Epidemiology, Medication, and Companies by DelveInsight - The Globe and Mail
Leptomeningeal Metastases Drugs Market 2034: EMA, PDMA, FDA - openPR
Eli Lilly acquires cancer program from Scorpion Therapeutics in $2.5B deal - STAT
Exclusive-Blackstone mulls $4 billion-plus sale of Liftoff, sources say - Yahoo Finance
Leptomeningeal Metastases Treatment Market 2034: EMA, PDMA, - openPR
Exclusive: Warburg Pincus explores $5 billion-plus sale of Modernizing Medicine, sources say - Reuters.com
Stevanato Group (NYSE:STVN) & Plus Therapeutics (NASDAQ:PSTV) Head to Head Review - Defense World
Are Broader Antibody Patents Possible in US Through Means-Plus-Function Claiming? - JD Supra
Simulations Plus (SLP) Fell due to Concerns Over the Funding Environment - Yahoo Finance
STAT6 stat sig? Kaken, J&J $1.2B-plus deal adds oomph to space - BioWorld Online
Viracta stock falls on strategic review (VIRX:NASDAQ) - Seeking Alpha
Sermonix and Henlius Dose First Chinese Patient in Phase 3 - GlobeNewswire
FDA Tracker: 2024 Ends With Lilly’s Landmark GLP-1 Sleep Apnea Approval - BioSpace
PSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to Shareholders - Business Wire
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 - GlobeNewswire
Plus Therapeutics Reports Promising 88% Response Rate in Phase 1 Cancer Treatment Trial - StockTitan
PSTV stock touches 52-week low at $1.12 amid market challenges - Investing.com UK
Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich’s Ataxia - GlobeNewswire
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients - Yahoo Finance
Investors in Padlock Therapeutics sue Bristol Myers Squibb over ‘milestone’ payments - STAT
Candel Therapeutics Stock Surges Over 100%Here's Why - Yahoo Finance
Candel Therapeutics Announces CAN-2409 Achieved Primary - GlobeNewswire
IO-202 Plus Azacitidine Elicits Responses in HMA-Naive Chronic Myelomonocytic Leukemia - OncLive
Plus Therapeutics (NASDAQ:PSTV) Price Target Lowered to $19.00 at Ascendiant Capital Markets - Defense World
Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash - The Manila Times
Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim - GlobeNewswire
Plus Therapeutics to Present Crucial Phase 1 Data for Novel Brain Cancer Treatment at Major Symposium - StockTitan
Plus Therapeutics Expands Strategic Agreement with Telix - GlobeNewswire
Plus Therapeutics Inc Azioni (PSTV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Plus Therapeutics Inc Azioni (PSTV) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hawkins Richard J | Director |
Sep 12 '24 |
Buy |
1.35 |
6,285 |
8,512 |
11,188 |
| Petersen Greg | Director |
Sep 11 '24 |
Buy |
1.35 |
12,500 |
16,875 |
48,921 |
| Clowes Howard | Director |
Sep 11 '24 |
Buy |
1.34 |
5,000 |
6,681 |
26,497 |
| HEDRICK MARC H | Chief Executive Officer |
Sep 10 '24 |
Buy |
1.23 |
8,000 |
9,839 |
20,425 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Sep 10 '24 |
Buy |
1.27 |
4,098 |
5,204 |
9,815 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
May 08 '24 |
Buy |
2.04 |
4,902 |
10,000 |
5,717 |
| HEDRICK MARC H | Chief Executive Officer |
May 08 '24 |
Buy |
2.04 |
12,255 |
25,000 |
12,425 |
| Petersen Greg | Director |
May 08 '24 |
Buy |
2.04 |
12,255 |
25,000 |
36,421 |
| Clowes Howard | Director |
May 08 '24 |
Buy |
2.04 |
9,804 |
20,000 |
21,497 |
| Hawkins Richard J | Director |
May 08 '24 |
Buy |
2.04 |
4,902 |
10,000 |
4,903 |
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):